Fortrea Buys Worldwide Early-Phase Unit For $45 Million, Expanding Texas Capacity

Fortrea has agreed to acquire the early-phase services division of Worldwide Clinical Trials for $45 million, adding assets that the company says will strengthen the front end of its phase 1 to 4 drug development platform.

According to Fortrea’s Wednesday release, the transaction includes Worldwide’s clinical pharmacology unit, bioanalytical laboratory operations, a 60,000-square-foot GLP bioanalytical lab, a 200-bed GCP-compliant clinical pharmacology unit and a biospecimen storage facility, all located in Texas. Fortrea said the acquired business will become part of its clinical pharmacology services business unit.

What Fortrea Is Buying

The strategic case is straightforward: Fortrea wants more control and capacity in early clinical development. The company said the acquisition should help it execute early-phase studies with fewer handoffs between clinical and bioanalytical functions, a change intended to streamline trial operations.

Fortrea also said the deal should give trial sponsors more flexibility for larger and more complex trials, better access to distinct patient populations and increased bedspace capacity. For a contract research organization operating across all phases of development in 100 countries, expanding owned early-phase infrastructure could make its platform harder to displace in programs that begin with first-in-human work and then continue into later-stage studies.

CEO Anshul Thakral described the purchase as an investment in early clinical development within Fortrea’s end-to-end platform supporting customers from first-in-human studies through Phase IV and post-approval evidence generation.

The Other Side Of The Deal

For Worldwide, the sale sharpens a different strategy. CEO Alistair Macdonald said the company hopes to use the funds to support late-stage work in oncology, neuroscience, internal medicine and rare disease.

That positioning matters because Worldwide has also been building around early-stage capabilities in other ways, including its January acquisition of Catalyst Clinical Research, a specialist oncology organization with expertise in early-stage cancer trials. Selling this division while reinvesting in later-stage priorities suggests Worldwide is narrowing where it wants to compete rather than trying to match broader platform CROs asset for asset.

Fortrea’s move also comes after a volatile period for the company since its 2023 spinoff from Labcorp. In that context, buying physical capacity and integrated early-phase operations looks less like expansion for its own sake and more like an effort to reinforce a service line that can anchor broader development work.